Forty-two compounds isolated from nine plants used within
Introduction
The blood-stage of the malarial parasite Plasmodium falciparum obtains the majority of the required essential amino acids by enzymic hydrolysis of haemoglobin, digesting up to 80% of the host cell's protein in the acidic lysosomal food vacuole. 1 The by-product of this digestion is the release of toxic haemin [Fe(III) protoporphyrin IX], which is detoxified in the lysosomal vacuole of the parasite via formation of an insoluble polymer, 'malarial pigment' or 'haemozoin', which is thought to be identical to synthetic β-haematin. [2] [3] [4] In the presence of preformed haemozoin, polymerization of haemin occurs spontaneously in vitro; 5 however, the involvement of a haemin polymerase enzyme 6 has not been disproven. Quinoline antimalarials, e.g. quinine and chloroquine, are generally thought to act by inhibiting the formation of haemozoin, either by binding to free haemin or by capping the ends of the growing complex. 2, 3 As a result haemin accumulates and kills the parasite. Recently, an alternative haemin detoxication mechanism has been described in the parasitized erythrocyte involving reactions of haemin with glutathione (GSH), 7 akin to the physiological mechanism for preventing damage by the low levels of free haemin in normal red blood cells. 8 Remarkably, quinoline antimalarial compounds can also inhibit this route of detoxication [9] [10] [11] or that dependent on peroxidation reactions. 12 In order to test the ability of compounds to interfere with haemin polymerization, two in vitro polymerization assays have been developed previously. One utilizes the formation of 'haemozoin' from concentrated haemin solution in aqueous dimethylsulphoxide (DMSO)/Na acetate (pH 5), the polymer being quantified spectrophotometrically. 13 The method is a good predictor of antimalarial activity, but takes 18 h and involves compound-haemin interaction at millimolar con-centration, which is not useful where there are limited quantities of test compound. A second method measures polymerized haemin radiochemically. 14 This method allows compound-haemin interaction with 0.1 mM [ 14 C]haemin, and has been used with advanced robotic workstations to screen large numbers of compounds from a library. 15 This method is suitable for a commercial operation, but is expensive and slow for academic studies and studies of natural products in short supply. Furthermore, the conditions of haemin concentration are still far above those able to differentiate a high-affinity interaction with haemin, which is likely to be in the sub-micromolar range, from many which occur in the 10-100 µM range.
In view of the current major threat from drug-resistant malaria, 16, 17 both novel drug targets and structurally diverse drugs, active at validated targets like haemozoin formation, are urgently needed. In order to facilitate screening for novel haemin-binding antimalarials, two new assays are presented: one is based on the inhibition of the reaction(s) of GSH with haemin; 9 the other on the reversal of the inhibition by haemin of the dopachrome tautomerase activity of human macrophage migration inhibitory factor (MIF). 18 The assays were tested successfully using a series of 42 compounds isolated from antimalarial plant extracts. 19 The methods offer improvements in sensitivity, speed and cost that should prove useful in antimalarial discovery.
Materials and methods
Haemin, GSH, L-dihydroxyphenylalanine-methyl ester, Na m-periodate, EDTA, diethylenetriamine-penta-acetic acid (DETEPAC), NaCl (ultrapure) and DMSO (molecular biology grade) were obtained from Sigma. Analytical grade Na phosphates, NaOH, ethane-1,2-diol, ethanol and methanol were obtained from BDH/Merck. 19 The compounds were structurally characterized 19 and tested for the ability to inhibit the proliferation, according to incorporation of [ 3 H]hypoxanthine into nucleic acids, of a chloroquine-resistant (K1) and a sensitive (T9-96) strain of P. falciparum cultured in vitro. 20 
Scanning spectrophotometry
The effect of GSH upon haemin was analysed by repetitive scanning spectrophotometry (Perkin-Elmer λ5) in the absence or presence of known haemin-binding antimalarial compounds. A solution (0.8 mL) of 10 µM haemin in 1 mM DE-TEPAC, 0.05 M Na phosphate pH 7.0 at 25°C in a cuvette of 1 cm light-path, was scanned from 480 to 340 nm. Neutralized GSH was added to 2 mM (using a 100 mM stock solution) and the sample scanned at 3 min intervals. The experiment was repeated in the presence of 18 µM chloroquine, mefloquine, quinine, bi-desethyl-amodiaquine, desbutyl-halofantrine or artemisinin. In each case the drug was added after the haemin scan, and an extra scan was made before the addition of GSH to show formation of a drug-haemin complex.
Multiwell plate GSH-haemin interaction assay
Based upon the spectrophotometric data, a multiwell assay for the inhibition of GSH-haemin interaction was developed. The following stock solutions were prepared: 1 mM DETEPAC in 10 mM Na phosphate pH 7.0; 2 mM haemin in DMSO; and 100 mM GSH, 1 mM DETEPAC, 10 mM Na phosphate pH 6.8. Drug stock solutions (generally 2 mM) were prepared in water, methanol or DMSO as required. All stocks were stored frozen except the haemin which was prepared fresh daily. Working solutions were as follows: 'A', DETEPAC/phosphate stock 4 vol + 1 vol ethanol; 'B', 5 µL haemin stock solution per mL of solution A; and 'C', 0.15 mL GSH stock solution per mL solution 'A'.
Assays were carried out in 96-well (400 µL) flat-bottomed polystyrene plates. Solution A (100 µL) was added, followed by drug or solvent control (e.g. 2 µL of 2 mM drug stock) in triplicate assays. Solution B (haemin) (200 µL) was then added to all wells using a multichannel pipette followed by 50 µL solution C (GSH). Final concentrations of drug and haemin were 11 µM and 5.7 µM, respectively. The absorbance at 360 nm (A 360 ) was measured after c. 1 min using a plate reader (MCC Titertek, Thermo Life Sciences, Basingstoke, UK) set up to read at t = 0 and t = 30 min and to calculate the ∆A 360 . The A 360 of the controls (GSH + haemin + solvent ) decreased by about 0.08. The effect of the haemin-binding compounds was evaluated as the percentage decrease compared with control absorbance. Mean and S.D. of the triplicates were calculated and significance determined by Student's t-test.
MIF-haemin interaction assay
The following stock solutions were prepared: 'D', 40% (v/v) ethane-1,2-diol, 1 mM EDTA, 20 mM Na phosphate pH 6.8; 'E', 1 mM EDTA, 10 mM Na phosphate pH 6.4; 'F', 10 mM L-dihydroxyphenylalanine-methyl ester in water; and 'G', 20 mM Na m-periodate in water. Recombinant human MIF was dissolved (0.5 mg/mL) in 'D'. All solutions were stored at 4°C. A working solution of MIF (7.5 µg/mL) was prepared daily by diluting the stock with 'D', and kept on ice. Haemin (0.2 mM in DMSO) was also prepared daily. Tautomerase activity was assayed at 35°C in thermostatted 1 mL polystyrene cuvettes at 474 nm. To 740 µL solution E was added 32 µL solution F, stirred, then 24 µL solution G was added and stirred to form c. 0.4 mM L-dopachrome-methyl ester, all of the periodate ('G') being consumed. A control volume of DMSO (4 µL) was added and the rate of spontaneous dopachrome decarboxylation was measured by the decrease in A 474 over 0.4 min. MIF (2 µL i.e. 15 ng) was added with stirring and the dopachrome tautomerization followed similarly to obtain an uninhibited control rate. In order to check for direct inhibition of tautomerization by the test compound, which would preclude that compound from this type of assay, the assay was repeated using a maximal level of test compound (e.g. 2 µL of 2 mM in DMSO + 2 µL DMSO). If there was little or no inhibition, the original assay was repeated with c. 2 µL haemin, such that the activity due to MIF was inhibited by 75-95%. The test compound (maximal amount) and haemin were then both included in the assay to see whether there was reversal of the haemin-dependent inhibition of the MIF tautomerase activity. In positive cases, successive twofold reductions in the concentration of test compound gave a 'reversal of inhibition curve' and the concentration causing 50% relief of the inhibition, 'RI 50 ', was obtained graphically.
Results
The reaction of haemin with GSH at pH 7.0 was monitored spectrophotometrically (Figure 1a) . The broad absorption of 10 µM haemin from 360 to 390 nm was immediately changed to a peak at 364 nm upon addition of GSH. During the next few minutes this peak decreased with a slight increase at Figure 1 . Effects of quinoline drugs upon spectral changes occurring during the reaction of haemin with GSH. (a) The visible spectrum of 10 µM haemin in buffer A at 25°C was recorded. GSH was added to 1.8 mM and the spectral change recorded within 2 min. The sample was then rescanned at 3 min intervals. (b-f) The experiment was repeated in the presence of 18 µM of quinine, mefloquine, desbutyl-halofantrine, bi-desethylamodiaquine or chloroquine, respectively, the drugs being added before the addition of GSH. 450 nm and isosbestic points at 403 and 500 nm. Thence, further decreases at 364 nm were associated with loss of the isosbestic point at 403 nm and further small increases in the region of 450 nm, indicating that at least two processes had occurred. By 30 min, the A 364 was lowered to approximately half and there was little further decrease at 364 nm. Inclusion of antimalarial alkaloids (18 µM), added before the GSH addition (Figure 1b-f) resulted first in the alteration of the haemin spectrum due to the immediate formation of alkaloidhaemin complexes, and then to altered effects of GSH. In the cases of halofantrine, amodiaquine and chloroquine, the addition of GSH then failed to result in formation of the 364 nm peak (Figure 1d-f) and there was little change in their spectra over 30 min. In the presence of quinine (Figure 1b) , the 364 nm peak was formed at a lower level than control (Figure 1a) , and decreased less over time. Mefloquine (Figure 1c) showed effects intermediate between those of quinine and halofantrine/ amodiaquine/chloroquine. The data extend earlier observations of changes at 400 nm, 9 and indicate that it would be possible to detect haemin-binding antimalarials from the decreased loss of absorbance of GSH-haemin at 364 nm over 30 min, regardless of the spectrum of any preformed alkaloidhaemin complex. The ∆A 364 /cm is 0.35 in the above assays at 10 µM haemin, so it was considered possible to use about half that amount of haemin and adapt the assay for a multiwell plate reader with optical path-length of c. 0.5 cm to give a control absorbance decrease of c. 0.1. Such an assay is shown in Figure 2 using a plate reader equipped with a 360 nm filter in kinetic mode. Triplicate assays were prepared in a 96-well plate. The A 360 was measured at 1 and 30 min after addition of GSH and the ∆A 360 calculated. The method clearly distinguishes the haemin-binding antimalarials, which inhibit the loss of A 360 by >40%, from the other drugs. The method detects drug-haemin interaction in the 10 µM range, which should be capable of detecting both high-and moderateaffinity haemin-binding antimalarials. Artemisinin, which reacts more weakly with haemin than with haem, 21, 22 caused only 20% inhibition of the GSH-dependent loss of haemin in this assay. More detailed analysis of the effect of artemisinin by repetitive scanning spectrophotometry confirmed a low level of complexation and a 20% decrease in haemin-GSH reaction rate, which was incomplete at 30 min.
In order to test for haemin-binding compounds biochemically with a sensitivity that might correlate with antimalarial effects in cellular assays, we utilized the inhibition by haemin of the tautomerase activity of MIF (I 50 0.15 µM 18 ). As predicted, the haemin-binding alkaloids were able to reverse the inhibition of MIF tautomerase activity. A standardized assay was developed in which the control activity was inhibited by haemin to c. 85% (75-95% in practice) and various concentrations of drug were added to obtain a reversal of inhibition curve, and an 'RI 50 '. Several antimalarial drugs were tested and reversal of inhibition was detectable with as little as 70 nM chloroquine (Figure 3) . In this assay, a maximum of 0.6% (v/v) DMSO + methanol was used to avoid solvent inhibition of MIF and this led to solubility problems with some drugs such as lumefantrine for which a complete relief of inhibition curve could not be obtained.
The novel assays were tested using a group of 42 compounds isolated from plants that are used for malarial therapy in South America. 19 The structures of the compounds had been fully or partially characterized, and analysed for antiplasmodial activity in cellular assays using two strains of P. falciparum (K1 and T9-96) in comparison with chloro- Figure 2 . Test of multiwell plate GSH-haemin interaction assay. The effect of various drugs (11 µM) on the decrease in A 360 due to interaction of 1 mM GSH with 5.7 µM haemin was determined as described in the text using a plate reader. Values are the mean of triplicate assays, which differed by <5%. quine and quinine. 19 The group comprised 14 bis-benzylisoquinolines (BBIQs), one benzyl-isoquinoline, one quarternary-benzyl-isoquinoline, three β-carboline, nine indole alkaloid, three aporphine, two protoberberine, six terpenoid, one quassinoid, one coumarin and one unknown.
The percentage of GSH-dependent loss of A 360 in the presence of each of the 42 compounds was compared with the IC 50 of antiplasmodial activity in the T9-96 (Figure 4a ) and K1 (Figure 4b ) strains of P. falciparum. Compounds that inhibited growth by <50% at 40 µM were grouped as being not significantly growth inhibitory (IC 50 > 40 µM). Twentyone of the compounds showed ≥40% inhibition of the effect of GSH on haemin (13 bis-benzyl-isoquinoline, three β-carboline, two protoberberine, two indole-alkaloid and one aporphine). Four compounds (two indole alkaloids and two β-carbolines) were positive in the GSH-haemin interaction assay but failed to show significant inhibitory activity against either strain of P. falciparum (IC 50 > 40 µM). In addition one compound (aporphine) was inhibitory only towards the K1 strain, and another (protoberberine) was inhibitory only towards the T9-96 strain. Inhibition of the GSH-haemin reactions correlated well with antiplasmodial activity (Table 1) . Thus, only 3/19 antiplasmodial compounds failed to inhibit GSH-haemin reaction by >40%: an indole alkaloid of relatively low antiplasmodial activity, the benzyl-isoquinoline and the least potent of the antiplasmodial BBIQs.
From the results summarized in Table 1 , the sensitivity of the GSH-haemin interaction assay was 0.85, the specificity was 0.82, the positive predictive value was 0.81 and the negative predictive value 0.86.
Eight of the 17 compounds showing both antiplasmodial activity and inhibition of GSH-haemin reaction were chosen to represent a range of potency for testing in the MIF-haemin interaction assay (i.e. the reversal of haemin inhibition of MIF dopachrome tautomerase activity). The log [RI 50 ] of the test compounds, together with those of chloroquine and quinine were positively correlated with the log[antiplasmodial IC 50 ] for theT9-96 strain (r = 0.824) and the K1 strain (r = 0.904) ( Figure 5 ).
Discussion
The spectrophotometric studies (Figure 1 ) confirmed and extended the observations of Atamna & Ginsburg 7 that GSH interacts in a complex way with haemin, and this is inhibited by haemin-binding compounds, which also disrupt haemin polymerization and show antimalarial properties. Although the nature of the GSH-haemin interaction remains unclarified, we have utilized the characteristic spectral changes to develop a simple test for haemin-binding compounds. This assay successfully detected 9/9 known haemin-binding antimalarials (>40% inhibition of GSH-dependent decrease in A 360 ) and excluded all three non-haemin-binding drugs (Figure 2 ). Taking Figure 4 . Screening of phytochemicals for inhibition of GSH-haemin interaction. Forty-two purified plant products 19 were tested for inhibition of the interaction of GSH with haemin using the multiwell plate assay as described in the text and the caption to Figure 2 . Inhibitory effects are compared with their ability to inhibit growth in vitro (IC 50 ) of strains of P. falciparum (a) T9-96 and (b) K1. IC 50 values of compounds that gave <50% inhibition of growth at 40 µM were not determined accurately. They are not considered to cause significant inhibition of growth and are plotted at 40 µM to indicate >40 µM. Four groupings are identified: samples considered positive in both assays (empty circle) showed an IC 50 of <40 µM and allowed maximally 60% of GSH-haemin reaction; samples showing positive in the GSH-haemin assay but with IC 50 of >40 µM (filled circle); samples negative in both assays (empty triangle); and samples negative in the GSH-haemin assay, but with an IC 50 of <40 µM (filled triangle).
Table 1. Correlation of GSH-haemin interaction inhibition with antiplasmodial IC 50
The ability of 42 isolated compounds to inhibit the reaction of haemin with GSH, determined using the plate-reader assay as described in the text, is compared with their ability to inhibit the in vitro growth of two strains of P. falciparum. 19 GSH-haemin effect <60% of control GSH-haemin effect >60% of control P. falciparum IC 50 < 40 µM in T9-96 or K1 17 (40.5%) true positive 3 (7.1%) false negative P. falciparum IC 50 > 40 µM in T9-96 and K1an inhibition of 40% as a significant effect on the GSHhaemin interaction, it failed to detect artemisinin, which gave only 20% inhibition. Such compounds could also be included in the positives if a higher level of false positives was acceptable. The GSH-haemin interaction assay is sensitive in the 10 µM range and is simple, cheap and fast.
In order to test the practical performance of the assay, 42 natural compounds isolated from species of antimalarial plants were screened. The assay successfully detected 16 of the 19 showing antiplasmodial activity in vitro. Among the three 'false negatives', one was a derivative of the indole alkaloid geissoschizoline, 23 which was only weakly antiplasmodial, and was similar structurally to ajmaline, another weak antimalarial. There was no obvious reason for failing to detect the other two, a benzyl-isoquinoline, (S)-6-methoxyjuziphine, and a partially characterized BBIQ from C. ovalifolia. 19 Six compounds inhibited the GSH-haemin interaction without showing antiplasmodial activity towards either strain. However, two of these, including the only potent inhibitor, a protoberberine, fargarine IV, were antiplasmodial towards only one of the strains. The other four comprised two partially characterized indole alkaloids from A. excelsum and two β-carbolines from S. amara, one of which was a glycoside. 19 This test may clearly give positive results for various compounds with a hydrophilic moiety such as glycosides, which will be unlikely to have antiplasmodial activity in vitro. A group of 10 myricetin and quercetin glycosides were also isolated from the aqueous acetic acid-soluble fraction of methanol extracts (non-alkaloidal) of M. dubia. 19 As expected, they showed no antiplasmodial activity in vitro; however, they were potent inhibitors of the GSH-haemin reaction, even at sub-stoichiometric levels of glycoside, which may be due to an antioxidant effect. Compounds of this type are expected to increase the numbers of 'false positives' in the GSH-haemin interaction assay, but could perhaps be detected by their substoichiometric potency.
The sensitivity of the GSH-haemin interaction assay is not high enough to cover the range of association constant of most useful haemin-binding antimalarials. In order to obtain information on the relative haemin affinity of compounds detected in the above assay, a more sensitive test was devised, namely the relief of haemin inhibition of the dopachrome tautomerase activity of human MIF, or 'MIF-haemin interaction assay'. This assay successfully detected the predicted haemin binding of all the antimalarials tested (Figure 4) although the RI 50 of lumefantrine could not be obtained due to its insolubility above 0.5 µM under these conditions. This assay is carried out in 99.5% aqueous solution generally in the range 50 nM to 5 µM of inhibitor with c. 200 nM haemin. The reversal of inhibition curve takes c. 1 h to obtain for each compound. The spectrophotometer is the only significant expense: only 150 ng MIF is needed per test compound at a cost of about £0.02.
Selecting eight of the compounds that gave a positive GSH-haemin interaction result for the MIF-haemin interaction assay, and adding chloroquine and quinine, RI 50 values were obtained. The log 10 of the RI 50 for the compounds is reasonably proportional to the log 10 of the antiplasmodial IC 50 in the two strains ( Figure 5 ) and is expected to be able to predict compounds capable of interacting with haemin at physiologically significant aqueous concentrations of haemin (submicromolar). The recombinant human MIF used in the assay is stable as a stock solution in 40% (v/v) ethan-1,2-diol, 10 mM Na phosphate for at least a year at 4°C.
Although the antimalarial activity of BBIQ compounds has been observed previously, 24, 25 their mode of action has not until now been related to their interaction with haemin.
It was considered that the GSH-haemin interaction assay could be used as a rapid screen for compounds binding in the micromolar range, and the inhibition of the MIF-haemin interaction assay could be used to test for sub-micromolar potency of interaction in order to select compounds that would render worthwhile the more complex assays that are better predictors of antimalarial activity. 13, 20 The MIF-haemin interaction assay, although not suitable for high-throughput screening, should be useful as an aid in the identification of the most potent haemin-binding natural or synthetic products, which could then be selected for structural characterization where needed, and further testing. 13, 20 The assay should also be most useful when a very small amount of test compound is available. The novel assays described are unlikely to predict antimalarial activity as well as those involving direct inhibition of haemin polymerization; 13, 14 however, they have important advantages in terms of sensitivity, speed, simplicity and cost. Both assays depend on interactions thought to occur during plasmodial infection, and since MIF is present in human erythrocytes (c. 15 µg/mL, D. J. Meyer, unpublished) and may act as a proinflammatory cytokine, its release from parasitized or lysed erythrocytes could contribute to the symptoms of malaria. If this is the case, the interaction of MIF with haemin and its prevention by haemin-binding antimalarials might be of direct therapeutic significance.
